

LAHIVE
&
COCKFIELD
LLP

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN FORAN SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
LISA DIROCCO TYNER
HATHAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. McKENNA
VINCENT P. LOCCISANO
JAMES M. MCKENZIE

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

6P1614
PATENT AGENTS
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.
CHRISTOPHER E. DRABIK

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
JAMES H. VELEMA
W. ELANA WANG
CYNTHIA M. GILBERT

* Admitted in TX only
** Admitted in CT only

October 15, 2004

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 09/852,966
For: *USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN
PRESERVATION*
Inventors: Kaddurah-Daouk, Rima
Filed: May 10, 2001
Our Ref. No.: AVZ-020CNRCE

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. PTO Form SB/08;
3. Australian Search Report;
4. Copies of all publications cited in PTO Form SB/08 (4); and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to:
MS Amendment, Commissioner for Patents, P.O. Box 1450,
Alexandria, Virginia 22313-1450 on:

October 15, 2004

Date

Cynthia M. Soroos, Esq. Registration No. 53,623

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

Cynthia M. Soroos, Esq.
Registration No. 53,623
Attorney for Applicant



Australian Government

IP Australia

Discovery House, Phillip ACT 2606
PO Box 200, Woden ACT 2606
Australia
Phone +612 6283 2999
Facsimile +612 6283 7999
www.ipaustralia.gov.au

10 February 2004

Ms Lea Lewin
Baldwin Shelston Waters
Level 21
60 Margaret Street
SYDNEY NSW 2000

RECEIVED			
BSW SYDNEY			
11 FEB 2004			
Mail No: 277138			
To	Initials	Action	Date

Your Ref : 34246AUP00

Examiner's first report on patent application no. 57616/00
by AVICENA GROUP, INC.

Last proposed amendment no. 2

Dear Ms Lewin,

I am replying to the request for examination. I have based this report on the pamphlet and the statement of proposed amendments under S104 of 23 January 2003. I have examined the application and I believe that there are lawful grounds of objection to the application. These grounds of objection are:

1. The claims in general are unclear because no clear limitation can be placed on the term "skin disorder." Given that creatine was well known for treating a wide variety of skin "ailments" before the priority date of the claim, it is unclear if the invention is supposed to reside in treating different disorders than the many it is known for.
2. The invention as generally claimed lacks novelty and an inventive step in the light of:
 - a) ☒ US 4772591 A (MEISNER) 20 September 1988,*
 - b) ☒ US 5847003 A (PTCHELINTSEV et. al.) 8 December 1998,
 - c) WO 95/26182 A (BEIERSDORF AG) 5 October 1995,
 - d) US 5702688 A (YU et. al.) of 30 December 1997 (essentially similar disclosure to US 5883128 of 16 March 1999 and US 5886041 A of 23 March 1999, both cited against the corresponding US and EP application, and discussed in the IPER,
 - e) WO 97/42960 A (AVON PRODUCTS INC) 5 December 1997,
 - f) WO 97/12591 A (BEIERSDORD AG) published 10 April 1997,

* Cited against the corresponding US and WO applications.

all of which disclose the use of creatine (individually or in conjunction with other active ingredients) for the treatment of a wide variety of skin disorders. By definition the compositions *per se* are also disclosed.

The following documents, all cited in the ISR, all disclose the use of creatine in compositions for treatment of cancers and related ailments. It would appear that a person skilled in the art would at least consider that such compositions would have potential in treating skin disorders such as skin cancers. Even if this is not the case, the compositions *per se* could be used for such methods:


- g) ✓ WO 92/08456 A (AMIRA INC) 29 May 1992,
- h) ✓ US 5321030 A (KADDURA-DAOUK et. al.) 14 June 1994,
- i) ✓ WO 94/16687 A (THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA) 4 August 1999, and
- j) ✓ US 5676978 A (TEICHER et. al.) 14 October 1997.

3. There is no Notice of Entitlement on file. You will need to file one because an application without a Notice of Entitlement cannot be accepted.

I apologise for your application not being considered within the time set out in our Customer Service Charter. Currently the time between request and examination for all work in this technology is beyond that set out in the charter. We are refining our processes and reviewing our work distribution to address these delays.

You have 21 months from the date of this report to overcome all my objection(s) otherwise your application will lapse. You will need to pay a monthly fee for any response you file after 12 months from the date of this report.

Yours sincerely,



GRAEME J. BROXAM
Examiner of Patents, Section B2
Telephone: (02) 6283 2133



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Kaddurah-Daouk, Rima

Serial No.: 09/852,966

Filed: May 10, 2001

For: *USE OF CREATINE OR CREATINE
COMPOUNDS FOR SKIN PRESERVATION*

Attorney Docket No.: AVZ-020CNRCE

Group Art Unit: 1614

Examiner: V.Y.Kim

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450


Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

October 15, 2004

Date of Signature and of Mail Deposit

By:


Cynthia M. Soroos, Esq.
Reg. No. 53,623
Attorney for Applicant

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicant and her Attorney have become aware of the following publications and information, cited in an Australian Search Report dated February 10, 2004 during the prosecution of 57616/00 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicant hereby submits these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form SB/08, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicant understands that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP



Cynthia M. Soroos, Esq.


Registration No. 53,623

Attorney for Applicant

28 State Street
Boston, MA 02109
(617) 227-7400

Date: October 15, 2004

EAH/CMS/MCA/les
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/852,966
				Filing Date	May 10, 2001
				First Named Inventor	Kaddurah-Daouk, Rima
				Art Unit	1614
				Examiner Name	V.Y. Kim
Sheet	1	of	1	Attorney Docket Number	AVZ-020CNRCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	F1	5,702,688	12-30-1997	Yu, <i>et al.</i>	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	F2	WO 95/26182 A1	10-05-1995	Beiersdorf AG		
	F3	WO 97/12591 A1	04-10-1997	Beiersdorf AG		
	F4	WO 97/42960 A1	11-20-1997	Avon Products Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--